Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...

Generalized optical meta-spanners empower arbitrary light paths for multitasking optical manipulation

Have you ever wished to drive microscopic matter along an arbitrarily tailored trajectory instead of just a circle? That's ...
Science Daily

This new camera captures what happens in a trillionth of a second

Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...

MicroCloud Hologram Inc. Develops Technology Based on Quantum Key Distribution Protocol and Quantum Random Number Generation Technology, Constructs Authentication System ...

MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, developed a technology based on quantum key distribution protocol and quantum random number ...

AAN 2026: frexalimab Phase II OLE data bolsters progressive MS ambitions

The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Medscape

First Positive Phase 3 Drug Trial for MOGAD

Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new ...

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints metClinically meaningful microbiome ...

Revolutionary Imaging Technique Unlocks Secrets of Matter at Extreme Speeds

A novel imaging method captures ultrafast events with unprecedented detail by combining laser encoding and AI reconstruction. Researchers have introduced a new imaging method that reveals far more ...

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026(TM)

Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at ...

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a ...

AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease

While the primary motor endpoint showed modest improvement, more notable effects were observed in non-motor domains.
TechSpot

New magnetic field system enables wireless communication 100 meters underground

First look: South Korea's Electronics and Telecommunications Research Institute has reported a milestone in underground communications, demonstrating wireless data transmission 100 meters (328 feet) ...